Currently Viewing:
Newsroom
Currently Reading
AJMC in the Press, October 14, 2016
October 14, 2016 – AJMC Staff
Nearly Half of Pregnant Women Gained More Weight Than Recommended in 2015
October 13, 2016 – Mary Caffrey
What We're Reading: US Healthcare System Ranked 50th of 55 in Efficiency
October 04, 2016 – AJMC Staff
Medicaid Coverage Steadies, Private Managed Care Remains Significant
October 02, 2016 – Jackie Syrop
What We're Reading: Treasury Lost Funds in Favor of ACA Insurers
September 30, 2016 – AJMC Staff
AJMC in the Press, September 30, 2016
September 30, 2016 – AJMC Staff
Test Hepatitis C Patients for Hepatitis B Before Treatment, Panel Advises
September 26, 2016 – Christina Mattina
Clinical Trial Pioneers Transplantation of Hepatitis C-Infected Kidneys
September 24, 2016 – Christina Mattina
What We're Reading: CDC Reports Rising Use of Powerful Antibiotics
September 20, 2016 – AJMC Staff

AJMC in the Press, October 14, 2016

AJMC Staff
Coverage of our peer-reviewed research in the healthcare and mainstream press.
In the October 3, 2016, edition of Medical Economics, Mark L. Fuerst discussed the commentary in a special issue of The American Journal of Managed Care on novel direct-acting antivirals (DAAs). Darius Lakdawalla, PhD, of the University of Southern California’s Schaeffer Center for Health Policy and Economics, wrote that cost-sharing plans that impose large out-of-pocket costs on DAAs for patients with hepatitis C virus (HCV) are “suboptimal solutions,” because they impose financial burdens on patients “at a time when they are least able to cope with them.” For the rest of the special issue on policy questions surrounding HCV treatment and cost-sharing, click here.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up